UCSF Launches CANOPY, a 3,000-Person Study of Real-World Psychedelic Use: What It Means for Canadian Practitioners

Most of what clinicians know about psychedelics comes from tightly controlled trials: screened participants, pharmaceutical-grade compounds, trained facilitators, a room designed for the purpose. Most psychedelic use does not happen that way. On November 10, 2026, the University of California, San Francisco announced a study built around that gap.

The project, called CANOPY, will follow as many as 3,000 people around the world who have already decided to use a psychedelic, at home, at a retreat or elsewhere, and track their psychological outcomes for up to six months. The UCSF news release was issued on November 10, 2026 and distributed through EurekAlert the same day. As a Leader in Psychedelic News, ATMA CENA is covering it because it speaks to a question Canadian practitioners face every week: what should we make of patients who use psychedelics outside any clinical framework?

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334.

What UCSF announced

CANOPY is an observational study, not a clinical trial. According to the release, the researchers do not provide psychedelics and do not decide what participants take. They enrol adults who are already planning a psychedelic experience and who are willing to complete standardized assessments before use, after use, and over the following six months. The main study runs largely remotely, which is what makes a global enrolment target of 3,000 feasible.

The study spans a range of classic psychedelics and related compounds. The outcomes of interest are mood, well-being and other psychological measures. Participants who can travel to UCSF may also undergo brain imaging and EEG and give blood and saliva samples before their experience, and all participants may use wearable devices to collect physiological data. The enrolment page describes a brief version and an optional more thorough version of the study.

The study is led by Robin Carhart-Harris, PhD, a professor of neurology at UCSF. In the release, he describes CANOPY as "an opportunity to bring scientific rigor to these experiences at a scale we haven't had before," and frames the central question not as whether psychedelics can be beneficial but "for whom, under what circumstances, and why."

Who is paying, and why that matters

CANOPY is funded by an award of up to US$1.4 million from the Advanced Research Projects Agency for Health (ARPA-H), a federal agency within the US Department of Health and Human Services. It is one of three UCSF psychedelic projects sharing ARPA-H awards of up to US$8.5 million: a US$4 million study co-led by Carhart-Harris and Jennifer Mitchell, PhD, on how mindset and environment shape psychedelic effects, and a study of up to US$3.1 million, co-led by Mitchell and Lorenzo Pasquini, PhD, on psychedelics in older adults with low well-being and biomarkers associated with preclinical Alzheimer's disease.

The funding source is as notable as the study. A federal agency choosing to fund a naturalistic study of psychedelic use outside the clinic signals that funders now treat real-world use as a research question in its own right, not only a public-health problem to be discouraged.

Why a naturalistic study is different

Randomized trials remain the standard for establishing whether a treatment works, but they are poor at answering questions practitioners care about: who benefits and who is harmed when there is no screening, how much depends on preparation, setting and support rather than the drug, and what happens over months rather than weeks.

Observational cohorts can speak to those questions, with limits. Participants self-select; dose, purity and setting are reported, not controlled; and six-month follow-up will lose some participants. CANOPY will not tell anyone whether a psychedelic "works" for a given condition; what it can do, if enrolment and retention are strong, is describe the range of outcomes and the factors that predict them with far more power than existing naturalistic surveys. A recent US survey found that people with depression who used psychedelics often felt their care needs were unmet; CANOPY is a prospective attempt to put numbers on what happens next for people in that position.

What it means for Canadian practitioners

In Canada, legal access to psychedelic-assisted therapy outside clinical trials remains narrow and tightly restricted under federal controls, while unregulated use is common. Three practical implications stand out.

First, ask and document. Whatever a practitioner's view of unsupervised use, many patients are using psychedelics on their own. A non-judgemental history covering substance, dose, setting, preparation and any adverse experiences is now part of good psychiatric and primary-care assessment. CANOPY's structured before-and-after design is a reminder that outcomes depend heavily on what surrounds the dose.

Second, expect better data on risk. The field's safety knowledge comes mostly from trials that screened out people with psychosis risk, unstable cardiac disease and certain medications. A large real-world cohort is where signals about who is harmed, and under what conditions, are most likely to appear, and may sharpen contraindication and risk-reduction conversations in ways trial data cannot.

Third, the practitioner's role is widening. If the central question is now "for whom, under what circumstances, and why," then the skills that shape circumstances, including assessment, preparation, holding a session safely and integration, are precisely the skills regulators are asking training programs to define.

Two cautions. CANOPY is a research platform, not a service: nothing about it changes the legal status of any psychedelic in Canada, and the researchers neither supply substances nor direct anyone to use them. And the announcement is a launch, not a result; there are no findings yet, no peer-reviewed protocol and no stated timeline for first data. For now, CANOPY is a signal of where the research field, and a major US federal funder, are placing their attention.

Building the skills the question demands

For Canadian nurses, psychologists, physicians and therapists, the shift toward "for whom and under what circumstances" is a strong argument for structured training in assessment, preparation and integration. ATMA CENA's Advanced Pathways are complete programs that begin with the Psychedelic Therapy Foundations course; most courses are online, with an in-person immersive option offered in Calgary. Explore the psychedelic therapy training programs or book a call with a program advisor.

ATMA CENA, Leader in Psychedelic News.

Sources

1. UCSF launches large-scale study of psychedelics in the real world. University of California, San Francisco news release, via EurekAlert, 2026.
2. CANOPY Project: A Global Psychedelic Study (enrolment page). Carhart-Harris Lab, UCSF, 2026.
3. UCSF launches global study tracking real-world psychedelic experiences. News-Medical, 2026.